RCW 43.71C.010 Definitions. The definitions in this section apply throughout this chapter unless the context clearly requires otherwise. (1) “Authority” means the health care authority. (2) “Covered drug” means any prescription drug that: (a) A covered manufacturer intends to introduce to the market at a wholesale acquisition cost of ten thousand dollars or more for […]
RCW 43.71C.020 Health carriers—Cost and utilization data reporting. Beginning October 1, 2019, and on a yearly basis thereafter, a health carrier must submit to the authority the following prescription drug cost and utilization data for the previous calendar year for each health plan it offers in the state: (1) The twenty-five prescription drugs most frequently […]
RCW 43.71C.030 Pharmacy benefit managers—Data reporting. (1) By March 1st of each year, a pharmacy benefit manager must submit to the authority the following data from the previous calendar year: (a) All discounts, including the total dollar amount and percentage discount, and all rebates received from a manufacturer for each drug on the pharmacy benefit […]
RCW 43.71C.040 Pharmacy benefit managers—Compliance. (1) No later than March 1st of each calendar year, each pharmacy benefit manager must file with the authority, in the form and detail as required by the authority, a report for the preceding calendar year stating that the pharmacy benefit manager is in compliance with this chapter. (2) A […]
RCW 43.71C.050 Manufacturers—Data reporting. (1) Beginning October 1, 2019, a covered manufacturer must submit to the authority the following data for each covered drug: (a) A description of the specific financial and nonfinancial factors used to make the decision to set or increase the wholesale acquisition cost of the drug. In the event of a […]
RCW 43.71C.060 Manufacturers—Notice of new drug applications. (1) Beginning October 1, 2019, a manufacturer must submit written notice, in a form and manner specified by the authority, informing the authority that the manufacturer has filed with the FDA: (a) A new drug application or biologics license application for a pipeline drug; or (b) A biologics […]
RCW 43.71C.070 Manufacturers—Notice of price increases. (1) Beginning October 1, 2019, a manufacturer of a covered drug must notify the authority of a qualifying price increase in writing at least sixty days prior to the planned effective date of the increase. The notice must include: (a) The date of the increase, the current wholesale acquisition […]
RCW 43.71C.080 Pharmacy services administrative organizations—Data reporting. (1) Beginning October 1, 2019, and on a yearly basis thereafter, a pharmacy services administrative organization representing a pharmacy or pharmacy chain in the state must submit to the authority the following data from the previous calendar year: (a) The negotiated reimbursement rate of the twenty-five prescription drugs […]
RCW 43.71C.090 Enforcement. The authority may assess a fine of up to one thousand dollars per day for failure to comply with the requirements of RCW 43.71C.020 through 43.71C.080. The assessment of a fine under this section is subject to review under the administrative procedure act, chapter 34.05 RCW. Fines collected under this section must […]
RCW 43.71C.100 Annual report—Data confidentiality. (1) The authority shall compile and analyze the data submitted by health carriers, pharmacy benefit managers, manufacturers, and pharmacy services administrative organizations pursuant to this chapter and prepare an annual report for the public and the legislature synthesizing the data to demonstrate the overall impact that drug costs, rebates, and […]
RCW 43.71C.110 Rule making. The authority may adopt any rules necessary to implement the requirements of this chapter. [ 2019 c 334 § 13.]
RCW 43.71C.800 Joint state strategies—Development and implementation recommendations. The authority must contact the California office of statewide health planning and development and the Oregon department of consumer and business services to develop strategies to reduce prescription drug costs and increase prescription drug cost transparency. The authority must make recommendations to the legislature for implementing joint […]
RCW 43.71C.900 Findings—2019 c 334. The legislature finds that the state of Washington has substantial public interest in the following: (1) The price and cost of prescription drugs. Washington state is a major purchaser through the department of corrections, the health care authority, and other entities acting on behalf of a state purchaser; (2) Enacting […]
